Troriluzole

Troriluzole (trigriluzole) is an experimental medication that has been investigated as a potential treatment for spinocerebellar ataxia type 3 (SCA3),   obsessive-compulsive disorder,  and glioblastoma. It is a prodrug formulation of the medication riluzole.

Pharmacokinetics
While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.